^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IMP9064
i
Other names: IMP9064, IMP-9064, IMP 9064
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
IMPACT Therap
Drug class:
ATR inhibitor
Related drugs:
3ms
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=61, Recruiting, Impact Therapeutics, Inc. | Phase classification: P1/2 --> P1
Phase classification • Combination therapy • Metastases
|
senaparib (IMP4297) • IMP9064
3years
Burning Rock Collaborates with IMPACT Therapeutics to Provide Testing Services in Developing IMP9064 in both US and China (GlobeNewswire)
"Burning Rock Biotech Limited...today announced a collaboration with IMPACT Therapeutics where Burning Rock provides testing services in connection with IMPACT Therapeutics’ development of its ATR inhibitor IMP9064, which has received the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the Phase I/II clinical study, and will begin soon in the U.S. The collaboration will be supported by Burning Rock’s Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited labs in Guangzhou, China and California, U.S."
Licensing / partnership • IND • New P1/2 trial
|
IMP9064
Share via
